QUICK ANSWER · AEO / GEO
A KISS1-derived C-terminal decapeptide that can stimulate GnRH-linked reproductive-hormone responses. Small endocrine studies do not establish treatment efficacy for hypogonadism, fertility, libido or weight loss, and it is not a component of an FDA-approved drug.
ENTITY FACTS
What should readers identify first?
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
FAQ · ANSWER ENGINE
Frequently asked questions
What is Kisspeptin-10?
Kisspeptin-10 is described pharmacologically as Synthetic or endogenous C-terminal kisspeptin decapeptide and KISS1R/GPR54 agonist. A KISS1-derived C-terminal decapeptide that can stimulate GnRH-linked reproductive-hormone responses. Small endocrine studies do not establish treatment efficacy for hypogonadism, fertility, libido or weight loss, and it is not a component of an FDA-approved drug.
Does Kisspeptin-10 have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Kisspeptin-10 approved everywhere?
No global conclusion should be inferred. PrimeCore Class C must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.